Eligible patients were randomly assigned ( @:@ ) to receive either mFOLFOX@ plus bevacizumab ( on day @ of each @-week cycle , @ mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of @ mg/m ( @ ) oxaliplatin , @ mg/m ( @ ) l-leucovorin , @ mg/m ( @ ) bolus fluorouracil , and @ mg/m ( @ ) infusional fluorouracil ) or SOX plus bevacizumab ( on day @ of each @-week cycle , @ mg/kg intravenous infusion of bevacizumab and @ mg/m ( @ ) intravenous infusion of oxaliplatin ; assigned dose of S-@ twice a day from after dinner on day @ to after breakfast on day @ , followed by @-day break ) .